Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

Freedland, Stephen J.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Tutrone, Ronald F.; Venugopal, Balaji; Woo, Henry H.; Ramirez-Backhaus, Miguel; Supiot, Stephane; Lantz, Anna; Ganguli, Arijit; Ivanova, Jasmina; Kral, Pavol; Huang, Shu-Pin; Saad, Fred; Shore, Neal D.

doi:10.1056/evidoa2300251

NEJM Evidence

2023

DOI: 10.1056/evidoa2300251

|View full text |Cite

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

Stephen J. Freedland,

Martin Gleave,

Ugo De Giorgi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group

Giunta,

Roviello,

Conteduca

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group

Giunta,

Roviello,

Conteduca

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Tombal,

Gomez-Veiga,

Gomez-Ferrer

et al. 2024

European Urology Oncology

View full text Add to dashboard Cite

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Cordes,

Karzai,

Madan

2024

European Urology Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

Cited by 8 publications

References 29 publications

Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group

Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Contact Info

Product

Resources

About